Free Newsletter

FEATURES >> 10 largest U.S. patent losses | 15 top blockbuster contenders | Emerging pharma jobs

SPOTLIGHT: BMS selling off ConvaTec unit for $4.1B

May 5, 2008 — 5:59am ET

Tools

Bristol-Myers Squibb continues to off-load parts of its business that aren't directly related to its beef-up-biopharma strategy: the company has agreed to sell its wound and ostomy care division ConvaTec to a private equity partnership for $4.1 billion. Release | Report

SHARE
WITH:

Paid Research Reports

Trends in mHealth and Telemedicine
The Global Aesthetic Dermatology Market Outlook
Future Directions in Regenerative Medicine
Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline

More Research Reports >>